Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (DASL-HiCaP)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04136353 |
|
Recruitment Status :
Active, not recruiting
First Posted : October 23, 2019
Last Update Posted : July 28, 2023
|
Sponsor:
University of Sydney
Collaborators:
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Bayer
Cancer Trials Ireland
Canadian Cancer Trials Group
Memorial Sloan Kettering Cancer Center
Prostate Cancer Clinical Trials Consortium
Information provided by (Responsible Party):
University of Sydney
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Active, not recruiting |
|---|---|
| Estimated Primary Completion Date : | January 31, 2028 |
| Estimated Study Completion Date : | July 31, 2028 |